ATC Group: N05AX13 Paliperidone

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05AX13 in the ATC hierarchy

Level	Code	Title
`1`	N	Nervous system
`2`	N05	Psycholeptics
`3`	N05A	Antipsychotics
`4`	N05AX	Other antipsychotics
`5`	N05AX13	Paliperidone

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	6 mg
PAREN	Parenteral	2.5 mg	(depot)

Active ingredients in N05AX13

Active Ingredient
Paliperidone
Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Even though paliperidone is a strong D₂-antagonist, which is believed to relieve the positive symptoms of schizophrenia, it causes less catalepsy and decreases motor functions to a lesser extent than traditional neuroleptics.

Related product monographs

Document	Type	Information Source
BYANNLI Prolonged-release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)
INVEGA Prolonged-release tablet	MPI, EU: SmPC	European Medicines Agency (EU)
PALMEUX Prolonged-release suspension for injection	MPI, EU: SmPC	Health Products Regulatory Authority (IE)
XEPLION Prolonged release suspension for injection	MPI, EU: SmPC	European Medicines Agency (EU)